Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Current Assets (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Current Assets for 4 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 431.69% to $23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.4 million, a 431.69% increase, with the full-year FY2025 number at $15.0 million, changed N/A from a year prior.
  • Current Assets was $23.4 million for Q4 2025 at Neuphoria Therapeutics, up from $14.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $29.9 million in Q2 2022 to a low of $4.4 million in Q4 2024.
  • A 4-year average of $15.7 million and a median of $14.5 million in 2025 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 55.15% in 2023, then skyrocketed 431.69% in 2025.
  • Neuphoria Therapeutics' Current Assets stood at $29.9 million in 2022, then crashed by 55.15% to $13.4 million in 2023, then crashed by 67.25% to $4.4 million in 2024, then surged by 431.69% to $23.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Current Assets are $23.4 million (Q4 2025), $14.0 million (Q3 2025), and $15.0 million (Q2 2025).